NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | NaN | 32 | 22,471 | NaN |
| Interest income | NaN | 6,473 | 21,119 | NaN |
| Personnel expense | NaN | 10,373 | 30,415 | NaN |
| External r&d expense | NaN | 22,866 | 62,979 | NaN |
| Manufacturing expense | NaN | 9,980 | 13,321 | NaN |
| Regulatory expense | NaN | 545 | 3,134 | NaN |
| Commercial programs | NaN | 4,104 | 15,192 | NaN |
| General and administrative expense | NaN | 3,988 | 11,386 | NaN |
| Depreciation and amortization | NaN | 133 | 345 | NaN |
| Segment adjusted loss before tax | NaN | -45,484 | -93,182 | NaN |
| Share-based compensation expense | NaN | 14,023 | 45,402 | NaN |
| Change in fair value - derivatives | NaN | 15,335 | 3,448 | NaN |
| Loss on disposal of property, plant and equipment | NaN | NaN | -1 | NaN |
| Foreign exchange gains/(losses) | NaN | -82 | 218 | NaN |
| Loss for the period | -48,441 | -74,923 | -72,005 | -56,891 |
| Depreciation and amortization | 62 | 59 | 64 | 97 |
| Non-cash rent expense | -19 | NaN | 0 | 3 |
| Fair value change - derivative earnout and warrants | -5,942 | 15,335 | 23,792 | -20,344 |
| Loss on disposal of property, plant and equipment | -12 | -11 | -1 | NaN |
| Foreign exchange (gains)/losses | -1,613 | -82 | 218 | 12,919 |
| Amortization of premium/discount on available-for-sale debt securities | 10 | -24 | -396 | -985 |
| Share-based compensation | 18,002 | 14,023 | 15,010 | 30,392 |
| Changes in prepayments and other receivables | -15,219 | 10,064 | -2,614 | 5,830 |
| Changes in deferred revenue | NaN | 3,987 | 0 | -6,008 |
| Changes in accounts payable | -793 | 5,318 | -2,269 | 1,860 |
| Changes in accrued expenses and other current liabilities | -10,330 | 5,324 | 638 | -3,514 |
| Net cash used in operating activities | -30,604 | -40,875 | -32,769 | -74,139 |
| Maturities of available-for-sale debt securities | NaN | NaN | NaN | 37,163 |
| Purchase of property, plant and equipment, including internal use software | 38 | 100 | 42 | 104 |
| Maturities of marketable securities | 51,000 | 50,500 | 71,563 | NaN |
| Purchases of available-for-sale debt securities | NaN | NaN | NaN | 193,340 |
| Purchases of marketable securities | 62,471 | 71,541 | 225,192 | NaN |
| Net cash (used in)/provided by investing activities | -11,509 | -21,141 | 2,506 | -156,281 |
| Transaction costs on issue of ordinary shares and pre-funded warrants-December2024Offering | NaN | 0 | 0 | 1,586 |
| Proceeds from exercise of warrants | 651 | 1,180 | 274 | 184 |
| Proceeds from exercise of options | 10,414 | 12,504 | 5,618 | 11,346 |
| Net cash provided by financing activities | 11,065 | 13,684 | 5,892 | 9,944 |
| Net change in cash, cash equivalents and restricted cash | -31,048 | -48,332 | -24,371 | -220,476 |
| Foreign exchange differences | -1,332 | -60 | 12,819 | NaN |
| Cash, cash equivalents and restricted cash at the beginning of the period | 491,323 | 539,715 | 771,743 | NaN |
| Cash, cash equivalents and restricted cash at the end of the period | 458,943 | 491,323 | 539,715 | NaN |